Corcept Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CORT and other ETFs, options, and stocks.About CORT
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.
CORT Key Statistics
Stock Snapshot
Corcept Therapeutics(CORT) stock is priced at $35.79, giving the company a market capitalization of 3.76B. It carries a P/E multiple of 39.93.
During the trading session on 2026-01-07, Corcept Therapeutics(CORT) shares reached a daily high of $35.79 and a low of $35.78. At a current price of $35.79, the stock is +0.0% higher than the low and still 0.0% under the high.
Trading volume for Corcept Therapeutics(CORT) stock has reached 1.25K, versus its average volume of 4.23M.
The stock's 52-week range extends from a low of $32.99 to a high of $117.33.
The stock's 52-week range extends from a low of $32.99 to a high of $117.33.
CORT News
In late 2025, Corcept Therapeutics announced that the FDA issued a Complete Response Letter for its relacorilant NDA in hypertension secondary to hypercortisoli...
Nike, Inc. ( NKE ) shares rose 4.1% after CEO Elliott Hill revealed a recent purchase of roughly $1 million in company shares. NKE Corcept Therapeutics Incorpo...
Canaccord analyst Edward Nash lowered the firm’s price target on Corcept Therapeutics (CORT) to $99 from $140 and keeps a Buy rating on the shares after the FDA...
Analyst ratings
71%
of 7 ratingsMore CORT News
Corcept Therapeutics Incorporated ( ) shareholders that were waiting for something to happen have been dealt a blow with a 56% share price drop in the last mont...
The final day of 2025 saw the company get a sharp "no" from a top regulator. No biotech wants to exit a year with a regulatory rejection. Unfortunately for Cor...
Claim 70% Off TipRanks This Holiday Season Corcept Therapeutics ( (CORT) ) has shared an announcement. On December 31, 2025, Corcept Therapeutics announced th...
Biotech and Pharma Corcept Therapeutics Shares Plunge 50% After FDA Rejects Blood Pressure Drug In this article CORT The FDA declined to approve Corcept’s new d...
Wolfe Research analyst Kalpit Patel downgraded Corcept Therapeutics (CORT) to Underperform from Peer Perform with a $30 price target Published first on TheFly...
Corcept Therapeutics Incorporated (NASDAQ:CORT) stock tumbled Wednesday after the FDA rejection for relacorilant. The commercial-stage company is engaged in th...
Corcept Therapeutics (CORT) stock sank on Wednesday after the pharmaceutical company posted the Complete Response Letter (CRL) it received from the U.S. Food an...